Staar Surgical strengthens RA
This article was originally published in The Gray Sheet
Executive Summary
Eye product company hires James Farnworth as VP-quality, regulatory & clinical affairs Oct. 12. Farnworth will help resolve QSR compliance issues and trial monitoring violations cited at Staar's Monrovia, Calif. plant (1"The Gray Sheet" Oct. 4, 2004, In Brief). He formerly was director of regulatory affairs & quality assurance at Volcano Therapeutics. Quintiles still will be retained by Staar, whose Visian ICL intraocular lens awaits PMA approval...
You may also be interested in...
Staar Surgical Visian ICL
Implantable contact lens PMA approval for myopia likely will be delayed beyond the Oct. 22 American Academy of Ophthalmologists meeting, the firm says, following Sept. 23 receipt of 36 "FDA 483" observations stemming from a re-inspection of its Monrovia, Calif. manufacturing facility. An initial inspection led to a December 2003 warning letter and subsequent Staar corrections. Current observations include quality system and complaint handling issues. Staar is preparing a written response and will undertake further corrective action (1"The Gray Sheet" Sept. 20, 2004, p. 3)...
Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time
Small sterilizers told Medtech Insight that they were ready for the EPA’s controversial EtO emissions rule, while community advocates expressed concerns.
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.